A retrospective multicenter study assessing the efficacy of Enfortumab vedoth in in population of interest in patients with advanced Urothelial cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enfortumab vedotin (Primary)
Indications Bladder cancer; Squamous cell cancer; Urethral cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms UNITE Study

18 Feb 2023 Results (n=247) hypothesizing that the last systemic therapy prior to EV would impact outcomes, as pts treated with ICI immediately prior to EV would have superior outcomes relative to pts treated with chemotherapy presented at the 2023 Genitourinary Cancers Symposium
18 Feb 2023 Results (n=170) assessing the potential biomarkers of response to EV in a patient cohort in the UNITE dataset, presented at the 2023 Genitourinary Cancers Symposium.
09 Dec 2021 Results assessing efficacy of enfortumab vedotin in advanced urothelial cancer, published in the Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com